---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-004668"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:25:39.906479+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ZEO launches physician masterclass ahead of Florida's SB-1768 stem cell therapy law

## Summary
- Florida's SB-1768, effective July 1, 2025, permits MDs and DOs to offer non-FDA-approved stem cell therapies under strict compliance.
- ZEO's Masterclass on June 27, 2025, at NOVA Southeastern University educates physicians on SB-1768 compliance and clinical integration.
- Company positions itself as trusted supplier of compliant stem cell products via its FDA-registered facility.
- No financial guidance, revenue impact, or clinical trial results included in the announcement.

## SEC filing metadata
- accession: 0001829126-25-004668
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912625004668/0001829126-25-004668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912625004668/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-004668
- JSON: https://secwatch.observer/filing/0001829126-25-004668.json
- Plain text: https://secwatch.observer/filing/0001829126-25-004668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.